跳至主要内容
临床试验/NCT01392196
NCT01392196终止不适用

Renal Denervation in Patients With Chronic Heart Failure & Renal Impairment

Medtronic Vascular1 个研究点 分布在 1 个国家目标入组 39 人开始时间: 2011年10月1日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
入组人数
39
试验地点
1
主要终点
Safety of Renal Denervation in Heart Failure patients as measured by Adverse Events

研究概览

简要总结

This is a feasibility study enrolling up to 40 patients in Australia and Europe. The primary aim of the study is to demonstrate the renal denervation with the Symplicity Catheter is safe and determine the evidence of a response to renal denervation in patients with Heart Failure.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Heart Failure patients NYHA Class II or III
  • Renal Impairment Left Ventricular Ejection Function <40%
  • GFR 30 to 75 mL/min/1.73m2
  • Optimal stable medical therapy

排除标准

  • Renal artery anatomy must be eligible for treatment as determined by Angiography, and
  • History of prior renal artery intervention
  • Single functioning kidney.
  • Myocardial Infarction, unstable angina pectoris or cerebrovascular Accident within 3 months
  • Systolic BP < 90 mmHG

结局指标

主要结局

Safety of Renal Denervation in Heart Failure patients as measured by Adverse Events

时间窗: 6 month

次要结局

  • Ventricular function as measured by Echocardiography(6 month)
  • Renal function as measured by Glomerular Filtration Rate (GFR)(6 months)

研究者

发起方
Medtronic Vascular
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验